Skip to content

The application of functional magnetic resonance imaging technology in the prognosis of ocular ischemic diseases

The application of functional magnetic resonance imaging technology in the prognosis of ocular ischemic diseases

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022147
Enrollment
Unknown
Registered
2019-03-27
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular ischemic diseases

Interventions

ocular ischemic diseases patients:ASL Examination and CBF Measurement
Health people:ASL Examination and CBF Measurement

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Case group: Patients who diagnosed as ocular ischemic diseases and singed the inform consents. (2) Control group: Age-and gender-matched volunteers who singed the inform consents. (3) Aged 50-70 years. (4) Male or female.

Exclusion criteria

Exclusion criteria: (1) Those without clear FFA images due to refracting media problems such as leukoma, severe cataract, vitreous hemorrhage etc.. (2) Those unable to undergo nuclear magnetic resonance examinations: a. Those with the following devices installed or carried in their body, such as cardiac pacemaker, defibrillator, cardiac stent, artificial heart valve, metal clip after aneurysm operation, drug perfusion device implanted in vivo, any electronic device implanted in vivo (nerve stimulator, bone growth stimulator), intravascular embolization coil, filter, ECG recording monitor, metal suture, bullet or iron granule in vivo, fixed plate after fracture operation, and Steel nails, artificial limbs or joints, hearing aids, cochlear implants, middle ear implants, intraocular metal foreign bodies etc. b. Critical patients who suffer from claustrophobia or obnubilation and forbidden undergoing nuclear magnetic resonance examinations. (3) Those with the history of hemorrhage and cerebral infarction. (4) Those with the history of surgery within 3 months. (5) Those participating in other clinical trials within 3 months. (6) Those who disagree or decline to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Vision examination;Visual field examination;

Secondary

MeasureTime frame
Retinal thickness;CVI;ISI;

Countries

China

Contacts

Public ContactHongyang Li
faraway_sweet@163.com+86 13301333869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026